Quantitative Study of Antibiotic-Induced Susceptibility to

Size: px
Start display at page:

Download "Quantitative Study of Antibiotic-Induced Susceptibility to"

Transcription

1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 199, p /9/ $2./ Copyright 199, American Society for Microbiology Vol. 34, No. 7 Quantitative Study of Antibiotic-Induced Susceptibility to Clostridium difficile Enterocecitis in Hamsters H. E. LARSON* AND S. P. BORRIELLO Microbial Pathogenicity Research Group, Division of Communicable Diseases, Clinical Research Centre, Watford Road, Harrow, Middlesex, England HAI 3UJ Received 27 September 1989/Accepted 13 April 199 Commonly used antibiotics were compared for their ability to induce Clostridium difficile enterocecitis and death in hamsters. Susceptibility to infection with C. difficile was measured by calculating 5% lethal doses (in CFU) for hamsters for various intervals after antibiotic treatment. Infection occurred after very small doses of C. difficile were given to hamsters treated with clindamycin, ampicillin, flucloxacillin, and cefuroxime; there was little difference between the antibiotics in the degree of susceptibility that they induced. A large difference in the duration of susceptibility was observed, however, with susceptibility being temporary following ampicillin, flucloxacillin, and cefuroxime administration but long-lived following clindamycin administration. A larger dose of ampicillin, multiple doses of ampicillin, and a combination of antibiotics had comparatively small effects on the duration of susceptibility. C. dfficile growth and toxin production in in vitro suspensions of cecal contents were found to correlate closely with in vivo hamster infectivity. A persisting loss of colonization resistance following antibiotic treatment may be a type of postantibiotic effect. Although these results cannot be applied directly to humans, they suggest lines of further investigation into how antibiotics may differ in producing risks of C. difficile infection and pseudomembranous colitis in patients. Prior to the recognition that pseudomembranous colitis (PMC) was caused by Clostridium difficile, it was known to be a risk of antibiotic treatment, especially lincomycin and clindamycin (11). Discovery of the microbial pathogenesis of PMC (18) has permitted a more careful assessment of the relationship between antibiotic treatment and C. difficile infection (17). A large number of antibiotics have been found to facilitate infection in both animals and humans (2, 1). There has been suspicion that some antibiotics are more likely to result in C. difficile-associated disease than others. Aronsson et al. (1) compared the relative risk of antibiotics by determining the number of C. difficile toxin-positive cases relative to antibiotic sales in Sweden. In contrast, Pierce et al. (19) failed to find differences in the rates of antibioticassociated colitis after the administration of several antibiotics, although the power of that study to detect significant differences likely was small. Quantitative risk estimations in humans are bedevilled by problems of sample size, uncertainties about how much and how often antibiotics are actually consumed, differences in routes of administration, use of combination antibiotic therapies, and ignorance about whether individuals have actually been exposed to C. diffcile in their environments. We undertook an experimental quantitative comparison of various antibiotics using both in vivo and in vitro methods. It is known that oral vancomycin treatment makes hamsters susceptible to infection with very small doses of C. difficile (18). We determined the 5% lethal dose (LD5) for hamsters of C. difficile spores after administration of single oral doses of various antibiotics and assessed the capacity of suspensions of hamster cecal contents to support growth of C. difficile in vitro. * Corresponding author. MATERIALS AND METHODS C. difficile. Two strains (B-1 and H-1) of C. difficile isolated from patients with PMC and known to produce enterocecitis when administered to clindamycin-treated hamsters (17) were used in this study. Both strains produce toxins A and B. Antibiotic MICs were determined by a microdilution technique. For strain B-1 the MICs were as follows: clindamycin, 256,ug/ml; ampicillin,.5,ug/ml; flucloxacillin, 4,ug/ml; and cefuroxime, 128,ug/ml. Strain H-1 was inhibited by.13,ug of clindamycin per ml and.5,ug of ampicillin per ml. For inoculation of hamsters, a spore preparation was made from a 5-day Robertson cooked meat medium culture by using alcohol shock. The culture broth was centrifuged at 2, x g for 1 min, suspended in 5 ml of brain heart infusion (Difco Laboratories, Detroit, Mich.) with cysteine hydrochloride (BHIC;.5% [wt/vol]), mixed with 5 ml of 1% ethanol, held for 1 h at ambient temperature, and centrifuged again as described above. The pellet was washed once in BHIC and suspended in 5 ml of BHIC, and serial 1-fold dilutions in BHIC were prepared. The number of viable spores in the inocula was estimated by seeding.5 ml of diluted suspension on a blood agar plate (Difco), incubating it anaerobically at 37 C for 48 h in an anaerobic cabinet (Forma Scientific, Marietta, Ohio), and recording the number of colonies. Animals. Syrian hamsters obtained from breeding colonies at the National Institute for Medical Research, London, England, were individually maintained in sterilized filterlidded polycarbonate boxes (Stephen Clark Fabrications Ltd., Alva, Scotland) and were given autoclaved bedding, feed, and tap water (17). Wire cage floors were used to prevent coprophagia in one experiment. Antibiotic solutions and suspensions of C. difficile were administered orally in.25-ml volumes from the end of a 1-ml syringe. Antibiotics, as supplied for clinical use, were diluted in distilled water to yield 3 mg in.25 ml. All manipulations of antibiotic-treated animals were carried out with attention given to the preven Downloaded from on September 14, 218 by guest

2 VOL. 34, 199 QUANTITATIVE STUDY OF SUSCEPTIBILITY TO C. DIFFICILE 1349 tion of cross-contamination of infection from the environment of the animal holding unit. Control antibiotic-treated hamsters were inoculated with sterile broth after the inoculations of C. difficile were completed. Observations were continued for 7 days, at which time surviving animals were sacrificed. All animals were examined for evidence of cecitis İnfectivity calculation. Susceptibility of hamsters to C. difficile enterocecitis was measured by calculating the number of CFU required to produce enterocecitis in half of the animals inoculated with the highest dilution that produced disease. First, the LD5 was determined by challenging hamsters with log1o dilutions of a spore preparation after they were given a single oral dose of antibiotic. Three hamsters were challenged per dilution and observed as described above. The number of hamsters with enterocecitis at each dilution was recorded, and the Karber method of endpoint calculation was used to yield the LD5 (12). Second, the CFU in each dilution of the spore suspension was estimated as described above. The CFU, as determined by the estimated number of C. difficile at the endpoint dilution, was divided by the LD5, and this value was rounded to give the nearest whole CFU per 1 LD5. To conserve animals but still give a complete picture of the duration of susceptibility after various experimental variables, some challenges were performed with only a single large dose (14 CFU) of spores. Intervals after antibiotic treatment were selected for challenge that defined the duration of susceptibility, in days. In vitro suspensions. Suspensions of cecal contents for in vitro studies were prepared from freshly sacrificed hamsters who had received antibiotics but not C. difficile, as described previously (6). Briefly, cecal contents were removed from each of two hamsters for each day following antibiotic treatment, suspended to 1%o (wt/vol) in prereduced distilled water, and placed in bijoux in duplicate aliquots of 5. ml each. Logarithmic-growth-phase C. difficile was prepared by inoculating an overnight culture into fresh BHIC and incubating it anaerobically for 6 h at 37 C. This was centrifuged, washed in 2 ml of fresh broth, centrifuged, and suspended in 1 ml of fresh broth. The suspension was diluted 1:1, and 5 p.l was inoculated into each suspension of cecal contents. This inoculum typically contained 5 x 16 CFU. Suspensions of cecal contents were then incubated at 37 C anaerobically and examined for C. difficile growth at 48 h by a micromethod as described elsewhere (6). To test for toxin production, suspensions of cecal contents were centrifuged and supernatants were serially diluted twofold. One hundred microliters of each dilution was added to confluent monolayers of Vero cells in microdilution plates and observed at 24 and 48 h for evidence of a C. difficile toxin B cytopathic effect. To test for the possible presence of residual antibiotic, suspensions of cecal contents were centrifuged at 12,9 x g for 3 min, and supernatants were filtered through.45-,um-pore-size filters. Filtrates were inoculated, incubated, and tested for growth of C. difficile and toxin production in the same manner as described previously for suspensions of cecal contents (6). Some suspensions of cecal contents were assayed for clindamycin by the method of Roberts et al. (2), for ampicillin by using Sarcina lutea as the test organism, and for P-lactamase by the method of Rolfe and Finegold (21). TABLE 1. Calculation of LD5 of C. difficile B-1 2 days after a single 3-mg dose of clindamycin Dilution of C. difficile No. with enterocecitis/ No. of CFU/ spore suspension no. inoculated.5 ml inoculated 1-2 3/3 251 lo-3 3/3 41 lo-4 3/ / /3 1-7 /3 Broth only /2 RESULTS Hamsters given antibiotics followed by broth and those hamsters in the holding stocks that did not receive antibiotics remained well. Table 1 records the results of a sample experiment used to determine susceptibility to C. difficile B-1 2 days after a single oral, 3-mg dose of clindamycin. The LD5 per.25 ml of undiluted challenge inoculum was 4.8 (log1o). There was 4.7 CFU (log1o) in.25 ml of undiluted challenge inoculum. This yielded.8, or approximately 1, CFU/LD5. Table 2 summarizes the results of a series of similar experiments conducted at various intervals between antibiotic treatment and challenge with C. difficile. For up to 2 days after treatment, less than 1 CFU was needed to produce enterocecitis and death for all antibiotics listed in Table 2. After clindamycin treatment, hamsters remained susceptible to small doses of C. difficile for at least 14 days; these animals were maintained on wire cage floors. In contrast, animals treated with ampicillin and cefuroxime did not remain susceptible and were resistant to large doses of C. difficile by 3 days after antibiotic treatment. After flucloxacillin treatment, hamsters were still susceptible at 3 days. In one experiment, suspensions of C. difficile were administered immediately following the administration of ampicillin (Table 2, day interval). This produced susceptibility to 6 CFU of C. difficile. Since it appeared that antibiotics were distinguished by the duration rather than by the degree of susceptibility they produced, further experiments were performed by challenging the hamsters with a single large inoculation of C. difficile spores. Table 3 summarizes experiments which further compared various antibiotic regimens by challenging the hamsters with 14 spores at various intervals after antibiotic treatment was completed. Clindamycin-treated animals were still susceptible 74 days after a single 3-mg dose; these hamsters were not maintained on wire cage floors. An ampicillin dose of.3 mg did not produce susceptibility, whereas a dose of 3 mg produced susceptibility that lasted 2 days with evidence of recovery of resistance by 3 days. A TABLE 2. LD5 of C. difficile B-1 at various intervals after a single 3-mg dose of antibiotic Antibiotic LD5 (CFU) at the following intervals (days) Clindamycin 1 2 Ampicillin 6 8 >1 x 13 >2 x 13 Flucloxacillin 5 6 Cefuroxime 7 >1 x 14 Downloaded from on September 14, 218 by guest

3 135 LARSON AND BORRIELLO ANTIMICROB. AGENTS CHEMOTHER. TABLE 3. Susceptibility to C. difficile enterocecitis at various intervals after various doses of antibiotic treatment No. dying/no. inoculated at the following intervals (days) between Antibiotic Dose (mg) No. doses of antibiotic treatment and challenge: Clindamycin /3 3/3 Ampicillin.3 1 / /4 4/4 1/4 / /8 /8 /8 / /4 1/9 4/5 1/4 /4 /4 Flucloxacillin /6 7/8 2/ /4 2/4 3/4 1/4 /4 /4 Flucloxacillin + ampicillin /4 /4 /4 1-fold increase in the dose of ampicillin from 3 to 3 mg extended the period of susceptibility by only 1 day (seven of eight animals), and hamsters regained resistance to C. difficile by day 4. A single daily dose of 3 mg of ampicillin for 3 successive days produced an extended, although occasionally variable, susceptibility compared with those produced by the other regimens. By day 6 the animals were resistant to challenge. Flucloxacillin treatment produced results similar to those obtained with 3 mg of ampicillin, in that susceptibility persisted for 3 days. Flucloxacillin for 3 successive days, as with ampicillin, extended the period of susceptibility by 3 days. A fixed-dose combination of flucloxacillin and ampicillin did not increase the duration of susceptibility produced by flucloxacillin alone. To assess the role of clindamycin susceptibility in the development of enterocecitis, clindamycin-treated hamsters were challenged with a strain of C. difficile that was susceptible to clindamycin, strain H-1. Hamsters were resistant to challenge with more than 1i C. difficile spores 3 days after clindamycin treatment but were susceptible to 21 CFU 26 days after treatment. This degree of susceptibility was 1-fold less than that to C. difficile B-1. To study the correlation between the duration of susceptibility and antibiotic persistence, cecal contents of antibiotic-treated hamsters were assayed for antibiotic activity at various intervals after administration of a single 3-mg dose (Table 4). Clindamycin was detected up to 11 days after treatment. Concentrations at that time would have been sufficient to inhibit C. difficile H-1. In contrast, ampicillin was detected in low concentrations in two of five animals 1 day after treatment and not thereafter. P-Lactamase activity was detected in a single animal 3 days after treatment with ampicillin. Table 5 records the in vitro changes in numbers of C. difficile and toxin titers in suspensions' of cecal contents prepared from hamsters given antibiotics. The presence of toxin in the suspensions correlated significantly with growth (analysis of variance, P <.1, r =.87). There was no instance in which growth occurred but toxin was not produced. Suspensions from animals given.3 mg of ampicillin permitted neither C. difficile growth nor appreciable toxin production. This was not the result of residual antibiotic since filtrates of the suspensions all permitted growth and toxin production. Suspensions of cecal contents from animals given 3. mg of ampicillin were not inhibitory and permitted toxin production on days 1 and 2 after treatment but were inhibitory to growth and toxin production by day 3. Cefuroxime treatment resulted in stationary numbers without toxin production on day 1 and inhibitory suspensions of cecal contents on subsequent days. Ampicillin (3 mg) and flucloxacillin treatment resulted in suspensions of cecal contents that allowed growth and toxin production for a duration that was clearly longer than that after treatment with 3 mg of ampicillin. Some suspensions of cecal contents appeared to show partial effects either in growth or inhibition, and there were a few instances in which growth was inhibited but toxin was produced. Such findings are the result of averaging results for preparations from duplicate animals in which some suspensions of cecal contents were inhibitory and some permitted growth. Such mixed results were also evident in vivo, e.g., Table 3, days 3 through 6 after ampicillin treatment and days 3 through 7 after flucloxacillin treatment. DISCUSSION Although there is an extensive amount of information in the literature on the capacity of various antibiotics to induce C. difficile enterocecitis in hamsters (e.g., see references 2 TABLE 4. Assay for antibiotic activity in wet cecal contents at various intervals after a single 3-mg-dose Time (days) Clindamycin Ampicillin after Animal Concn Animal Concn activity treatment no. (Lg/g) no. (4/g) < <.4 4 < < < <.4 2 < <.5 2 < <.5 2 <.5 Downloaded from on September 14, 218 by guest

4 () * It l+i+ I+1I+ 1+ A -- 1.~1 t,4~~~~~-- '- C) ~ ~Di ~3 -j :I :PWO 'oo'ob 1+ R C o LQLaOb w z D w A6 " ") z 'I *N 1+ *- *. cl p o) oo) C t'i4 t - e z Z z 3 co oo 1+ **oi7 _) -3 It C) : + co _.D b3 i13:x bo _Q.. C Q *-I CI. DD B. z c c -. n (I (D DQ r-l 1v co DI. co. C) ai r md. (D, -. '. Di DiD - Xi _ DiD ' DiD U' (D F and 1), we are not aware of previous efforts to measure susceptibility or to use characterized challenge strains. By and large, previous investigators have allowed antibiotictreated animals to become infected fortuitously, although no doubt, with time, the environments of animal holding units become heavily contaminated with a predominant strain of C. difficile. The animal containment system we used prevents infection from ambient sources and permits challenge experiments with measured numbers of defined microorganisms at specified times. An earlier study, in which containment methods were used, showed that hamsters were susceptibile to a very small number of C. difficile after prolonged oral vancomycin treatment, whereas untreated hamsters were uniformly resistant to challenges with large doses of C. difficile (18). The current study considerably extended this approach and permits a quantitative measure of susceptibility after treatment with several commonly used antibiotics. The main findings are that all antibiotics tested produced susceptibility to very small doses of C. difficile but that these antibiotics differed to a smaller or greater extent in the duration of susceptibility after treatment. A 1-fold increase in the dose or the administration of three doses had a comparatively small effect on the duration of susceptibility. Persistence of susceptibility was not necessarily due to continued detectability of the antibiotic. Finally, the state of susceptibility was modeled in vitro, and the correlation with susceptibility in the animal was very strong. An effect on colonization resistance that outlasts detectable antibiotic activity may be a type of postantibiotic effect. Both clindamycin and ampicillin are associated with postantibiotic effects in other systems (8); clindamycin is known to produce the more prolonged effects and to act this way in vivo as well as in vitro. Prolonged excretion of active drug, active metabolites, or both may produce an especially strong effect. The mechanisms of the postantibiotic effect, and particularly, how they might apply in the gut, are not immediately obvious. A "postantibiotic effect" from clindamycin may simply be the elimination of the particular species responsible for colonization resistance. The data in Table 2 support the idea that susceptibility is an all-or-nothing state; reversion to resistance occurred rapidly. At some intervals after antibiotic treatment, individual differences in susceptibility were noted, especially in animals which had received multiple doses of ampicillin or flucloxacillin. It is not clear from the results of these experiments why individual animals might vary in their responses to multiple antibiotic doses. It is impossible from these experiments to say whether the apparent small differences in CFU/LD5O between clindamycin (1 and 2, Table 2) and the other antibiotics tested (5 to 8, Table 2) are real. Residual clindamycin activity in the gut appeared to inhibit infection with clindamycin-susceptible strain H-1. However, this strain had a slightly reduced capacity to infect hamsters even when clindamycin activity was undetectable. Clindamycin-susceptible strains of C. difficile are fully capable of causing illness in humans who receive clindamycin (9), but the onset of infection may be delayed until levels of antibiotic in the gut have abated. The occurrence of infection after treatment with ampicillin, to which all virulent strains are highly susceptible, has been ascribed to the induction of,b-lactamase in cecal contents (21). However, we found that small doses of C. difficile spores were able to induce disease immediately after a single oral dose of ampicillin, prior to the appearance of,b-lactamase. Overall, there seems to be no direct correlation between susceptibility to an antibiotic and Downloaded from on September 14, 218 by guest VOL. 34, 199 QUANTITATIVE STUDY OF SUSCEPTIBILITY TO C. DIFFICILE 1351

5 1352 LARSON AND BORRIELLO the capacity of a C. difficile strain to produce disease in either hamsters or humans (9). Borriello and Barclay (6) have shown in a clinical study that the growth of C. difficile in fecal suspensions in vitro parallels in vivo colonization. The correlation between the experiments reported in Tables 3 and 5 is striking. This suggests that the capacity of C. difficile to replicate in the fecal stream is a fundamental feature of the pathogenesis of the infection. The mechanism of resistance to colonization by C. difficile in untreated animals postulated by Borriello and Barclay (5, 6) requires the presence of viable microorganisms; it does not appear to be mediated by preformed bacterial products or metabolites that can be detected in fecal filtrates (5, 6). The very rapid onset of susceptibility noted in the present study is consistent with a requirement for viable organisms rather than soluble substances. Restoration of resistance after antibiotic treatment would then be the result of their regrowth. Mediation of resistance by means of viable microorganisms explains the apparently successful efforts to manage relapses of PMC by administering fecal suspensions by enema (7, 22). How might these results be applied to clinical situations? Differences between hamsters and humans limit the clinical applicability of our results. One difference concerns species variation in the way in which clindamycin is metabolized. In 15 patients given clindamycin intravenously (14) for 48 h perioperatively, levels were still present in feces and, indeed, were still increasing at day 5. Ten adult volunteers given oral clindamycin for 7 days (13) had substantial levels in feces 2 days after they concluded the course of therapy, but there was no detectable antibiotic activity at 9 days. The review of clindamycin by Klainer (16) emphasizes its fecal persistence and the potential role of this characteristic in the development of antibiotic-associated colitis. We found that clindamycin is detectable in hamsters 11 days after a single dose but not at 19 days. The human data suggest some persistence of the drug in feces, but not for as long as that which we observed in hamsters. A second difference concerns the normal gut flora in hamsters and humans responsible for excluding C. difficile. It is not known what specific microorganisms are responsible for colonization resistance in either hamsters or humans, even at the genus level (4). However, we have successfully restored hamster colonization resistance with a suspension of human faeces (H. E. Larson, unpublished data). The relevant microorganisms and susceptibilities may not be different in the two species, but this possibility needs to be confirmed. A third difference concerns coprophagia. Prevention of coprophagia did not shorten the duration of susceptibility after clindamycin treatment. We cannot be sure it did not hasten the return of colonization resistance after treatment with the other antibiotics. However, hamsters remained susceptible to clindamycin even when coprophagia was allowed. A fourth difference concerns the many more permutations of dose, frequency, and route of administration which are features of clinical use and which were not tested by our methods. Our results predict that differences in dose and frequency of administration are less important than the type of antibiotic, but this prediction might be overcome by very large doses or very long courses of treatment. One of the most striking of our findings was the very low infective dose of C. difficile required to initiate infection. After clindamycin treatment, we reproducibly found that only one or two microorganisms were needed. It is not known what dose of C. difficile is required to infect human subjects. It may be very low since nosocomial C. difficile ANTIMICROB. AGENTS CHEMOTHER. infections appear to occur as a consequence of exposure to contaminated fomites rather than to contaminated food or water. This is likely to mean ingestion of only a few microorganisms. We are not aware that the duration of susceptibility to C. difficile infection has previously been assessed as a risk factor for PMC. Prolonged susceptibility after antibiotic treatment offers more opportunity for exposure to and infection with C. difficile. It has not usually been possible to correlate the risk of C. difficile colitis with dose or duration of antibiotic treatment. This difficulty is most likely due to overriding differences in the degree to which at-risk patients have been exposed to environmental sources of C. difficile. Given the low rates of colonization in normal subjects, exposure to the organism is likely to be the single most important factor after antibiotic treatment that determines the risk of disease. The risk of exposure, however, is clearly related to the duration of susceptibility. PMC has been shown to occur after even short courses of cefoxitin given as perioperative infection prophylaxis (3). However, the postoperative duration of prophylactic antibiotic regimens is controversial, and PMC is their most important complication (15). We speculate that shorter rather than longer courses of antibiotic treatment could reduce the risk of complicating antibiotic-associated colitis. ACKNOWLEDGMENTS We thank A. Welch, F. Barclay, and H. Anderson for technical assistance and E. Goodband for typing the manuscript. LITERATURE CITED 1. Aronsson, A., R. MolHby, and C. E. Nord Clostridium difficile and antibiotic associated diarrhoea in Sweden. Scand. J. Infect. Dis. 35(Suppl.): Bartlett, J. G., T. W. Chang, N. Moon, and A. B. Onderdonk Antibiotic-induced lethal enterocolitis in hamsters: studies with eleven agents and evidence to support the pathogenic role of toxin-producing clostridia. Am. J. Vet. Res. 39: Block, B. S., L. J. Mercer, M. A. Ismail, and A. H. Moawad Clostridium difficile-associated diarrhea follows perioperative prophylaxis with cefoxitin. Am. J. Obstet. Gynecol. 153: Borriello, S. P Influence of the normal flora of the gut on Clostridium difficile, p In R. Grubb, T. Midtvedt, and E. Norin (ed.), The regulatory and protective role of the normal microflora. Macmillan, London. 5. Borriello, S. P., and F. E. Barclay Colonization resistance to Clostridium difficile infection. Microecol. Ther. 14: Borriello, S. P., and F. E. Barclay An in-vitro model of colonisation resistance to Clostridium difficile infection. J. Med. Microbiol. 21: Bowden, T. A., A. R. Mansberger, and L. E. Lykins Pseudomembranous enterocolitis: mechanism of restoring floral homeostasis. Am. Surg. 47: Craig, W. A., and B. Vogelman The postantibiotic effect. Ann. Intern. Med. 16: Dzink, J., and J. G. Bartlett In vitro susceptibility of Clostridium difficile isolates from patients with antibiotic-associated diarrhea or colitis. Antimicrob. Agents Chemother. 17: Fekety, R., J. Silva, R. Toshniwal, M. Allo, J. Armstrong, R. Browne, J. Ebright, and G. Rifkin Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters. Rev. Infect. Dis. 1: Gorbach, S. L., and J. G. Bartlett Pseudomembranous enterocolitis: a review of its diverse forms. J. Infect. Dis. 135:S89-S Hawkes, R. A General principles underlying laboratory diagnosis of viral infections, p In E. H. Lennette and Downloaded from on September 14, 218 by guest

6 VOL. 34, 199 QUANTITATIVE STUDY OF SUSCEPTIBILITY TO C. DIFFICILE 1353 N. J. Schmidt (ed.), Diagnostic procedures for viral, rickettsial and chlamydial infections, 5th ed. American Public Health Association, Washington, D.C. 13. Heimdahl, A., and C. E. Nord Effect of erythromycin and clindamycin on the indigenous human anaerobic flora and new colonization of the gastrointestinal tract. Eur. J. Clin. Microbiol. 1: Kager, L., L. Liljeqvist, A. S. Mahnborg, and C. E. Nord Effect of clindamycin prophylaxis on the colonic microflora in patients undergoing colorectal surgery. Antimicrob. Agents Chemother. 2: Kaiser, A. B Antimicrobial prophylaxis in surgery. N. Engl. J. Med. 315: Klainer, A. S Clindamycin. Med. Clin. North Am. 71: Larson, H. E., A. B. Price, and S. P. Borriello Epidemiology of experimental enterocecitis due to Clostridium difficile. J. Infect. Dis. 142: Larson, H. E., A. B. Price, P. Honour, and S. P. Borriello Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet i: Pierce, P. F., R. Wilson, J. Silva, Jr., V. F. Garagusi, G. D. Rifkin, R. Fekety,. Nunez-Montiel, Jr., V. R. Dowell, and J. M. Hughes Antibiotic-associated pseudomembranous colitis: an epidemiologic investigation of a cluster of cases. J. Infect. Dis. 145: Roberts, A. P., J. B. Eastwood, P. E. Gower, C. M. Fenton, and J. R. Curtis Serum and plasma concentrations of clindamycin following a single injection of clindamycin phosphate in maintenance haemodialysis patients and normal subjects. Eur. J. Clin. Pharmacol. 14: Rolfe, R. D., and S. M. Finegold Intestinal P-lactamase activity in ampicillin-induced, Clostridium difficile-associated ileocecitis. J. Infect. Dis. 147: Schwan, A., S. Sjolin, V. Trottestam, and B. Aronsson Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand. J. Infect. Dis. 16: Downloaded from on September 14, 218 by guest

ECOLOGICAL IMPACT OF NARROW SPECTRUM ANTIMICROBIAL AGENTS COMPARED TO BROAD SPECTRUM AGENTS ON THE HUMAN INTESTINAL MICROFLORA CARL ERIK NORD

ECOLOGICAL IMPACT OF NARROW SPECTRUM ANTIMICROBIAL AGENTS COMPARED TO BROAD SPECTRUM AGENTS ON THE HUMAN INTESTINAL MICROFLORA CARL ERIK NORD Old Herborn University Seminar Monograph 3: Consequences of antimicrobial therapy for the composition of the microflora of the digestive tract. Editors: Carl Erik Nord, Peter J. Heidt, Volker Rusch, and

More information

Effects of Minocycline and Other Antibiotics on Fusobacterium necrophorum Infections in Mice

Effects of Minocycline and Other Antibiotics on Fusobacterium necrophorum Infections in Mice ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1975, p. 421-425 Copyright 0 1975 American Society for Microbiology Vol. 7, No. 4 Printed in U.S.A. Effects of Minocycline and Other s on Fusobacterium necrophorum

More information

مادة االدوية المرحلة الثالثة م. غدير حاتم محمد

مادة االدوية المرحلة الثالثة م. غدير حاتم محمد م. مادة االدوية المرحلة الثالثة م. غدير حاتم محمد 2017-2016 ANTIMICROBIAL DRUGS Antimicrobial drugs Lecture 1 Antimicrobial Drugs Chemotherapy: The use of drugs to treat a disease. Antimicrobial drugs:

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY

More information

Burn Infection & Laboratory Diagnosis

Burn Infection & Laboratory Diagnosis Burn Infection & Laboratory Diagnosis Introduction Burns are one the most common forms of trauma. 2 million fires each years 1.2 million people with burn injuries 100000 hospitalization 5000 patients die

More information

USA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION

USA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS

More information

Test Method Modified Association of Analytical Communities Test Method Modified Germicidal Spray Products as Disinfectants

Test Method Modified Association of Analytical Communities Test Method Modified Germicidal Spray Products as Disinfectants Study Title Antibacterial Activity and Efficacy of E-Mist Innovations' Electrostatic Sprayer Product with Multiple Disinfectants Method Modified Association of Analytical Communities Method 961.02 Modified

More information

Should we test Clostridium difficile for antimicrobial resistance? by author

Should we test Clostridium difficile for antimicrobial resistance? by author Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first

More information

Prophylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi

Prophylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi Prophylactic antibiotic timing and dosage Dr. Sanjeev Singh AIMS, Kochi Meaning - Webster Medical Definition of prophylaxis plural pro phy lax es \-ˈlak-ˌsēz\play : measures designed to preserve health

More information

Antimicrobial Resistance in Human Oral and Intestinal Anaerobic Microfloras

Antimicrobial Resistance in Human Oral and Intestinal Anaerobic Microfloras ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1993, p. 1665-1669 Vol. 37, No. 8 0066-4804/93/081665-05$02.00/0 Copyright X 1993, American Society for Microbiology Antimicrobial Resistance in Human Oral and

More information

Running head: CLOSTRIDIUM DIFFICILE 1

Running head: CLOSTRIDIUM DIFFICILE 1 Running head: CLOSTRIDIUM DIFFICILE 1 Clostridium difficile Infection Christy Lee Fenton Mountainland Applied Technology College CLOSTRIDIUM DIFFICILE 2 Clostridium difficile Infection Approximately 200,000

More information

Principles of Antimicrobial therapy

Principles of Antimicrobial therapy Principles of Antimicrobial therapy Laith Mohammed Abbas Al-Huseini M.B.Ch.B., M.Sc, M.Res, Ph.D Department of Pharmacology and Therapeutics Antimicrobial agents are chemical substances that can kill or

More information

Comparison of Clindamycin, Erythromycin, and Methicillin in Streptococcal Infections in Monkeys

Comparison of Clindamycin, Erythromycin, and Methicillin in Streptococcal Infections in Monkeys ANTIbMCROBIAL AGENTS AND CHEMOTHERAPY, June 197, p. 460-465 Copyright 197 American Society for Microbiology Vol. 1, No. 6 Printed in U.S.A. Comparison of Clindamycin, Erythromycin, and Methicillin in Streptococcal

More information

Clostridium difficile Colitis

Clostridium difficile Colitis Update on Clostridium difficile Colitis Fredrick M. Abrahamian, D.O., FACEP Associate Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA

More information

Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci

Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci Journal of Antimicrobial Chemotherapy (78) 4, 53-543 Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci Chatrchal Watanakunakoni and Cheryl Glotzbecker Infectious

More information

Visit ABLE on the Web at:

Visit ABLE on the Web at: This article reprinted from: Lessem, P. B. 2008. The antibiotic resistance phenomenon: Use of minimal inhibitory concentration (MIC) determination for inquiry based experimentation. Pages 357-362, in Tested

More information

by adding different antibiotics to sera containing

by adding different antibiotics to sera containing J. clin. Path., 1977, 30, 521-525 Serum gentamicin assays of 100 clinical serum samples by a rapid 40 C Kiebsiella method compared with overnight plate diffusion and acetyltransferase assays D. C. SHANSONI

More information

Therapy of Staphylococcal Infections in Monkeys

Therapy of Staphylococcal Infections in Monkeys APuPED MICROBIOLOGY, Mar. 1971, P. 440-446 Copyright 1971 American Society for Microbiology Vol. 21, No. 3 Printed in U.S.A. Therapy of Staphylococcal Infections in Monkeys VI. Comparison of Clindamycin,

More information

Inappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012

Inappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012 Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton

More information

Influence of ph on Adaptive Resistance of Pseudomonas aeruginosa to Aminoglycosides and Their Postantibiotic Effects

Influence of ph on Adaptive Resistance of Pseudomonas aeruginosa to Aminoglycosides and Their Postantibiotic Effects ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1996, p. 35 39 Vol. 40, No. 1 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology Influence of ph on Adaptive Resistance of Pseudomonas aeruginosa

More information

GeNei TM. Antibiotic Sensitivity. Teaching Kit Manual KT Revision No.: Bangalore Genei, 2007 Bangalore Genei, 2007

GeNei TM. Antibiotic Sensitivity. Teaching Kit Manual KT Revision No.: Bangalore Genei, 2007 Bangalore Genei, 2007 GeNei Bacterial Antibiotic Sensitivity Teaching Kit Manual Cat No. New Cat No. KT68 106333 Revision No.: 00180705 CONTENTS Page No. Objective 3 Principle 3 Kit Description 4 Materials Provided 5 Procedure

More information

Recommended for Implementation at Step 7 of the VICH Process on 15 December 2004 by the VICH Steering Committee

Recommended for Implementation at Step 7 of the VICH Process on 15 December 2004 by the VICH Steering Committee VICH GL27 (ANTIMICROBIAL RESISTANCE: PRE-APPROVAL) December 2003 For implementation at Step 7 - Final GUIDANCE ON PRE-APPROVAL INFORMATION FOR REGISTRATION OF NEW VETERINARY MEDICINAL PRODUCTS FOR FOOD

More information

11/2/2015. Update on the Treatment of Clostridium difficile Infections. Disclosure. Objectives

11/2/2015. Update on the Treatment of Clostridium difficile Infections. Disclosure. Objectives Update on the Treatment of Clostridium difficile Infections Spencer H. Durham, Pharm.D.,BCPS (AQ-ID) Assistant Clinical Professor of Pharmacy Practice Auburn University Harrison School of Pharmacy Kurt

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/MRL/728/00-FINAL April 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS STREPTOMYCIN AND

More information

SURGICAL ANTIBIOTIC PROPHYLAXIS GUIDELINES WITHIN ORTHOPAEDIC SURGERY FOR ADULT PATIENTS

SURGICAL ANTIBIOTIC PROPHYLAXIS GUIDELINES WITHIN ORTHOPAEDIC SURGERY FOR ADULT PATIENTS SURGICAL ANTIBIOTIC PROPHYLAXIS GUIDELINES WITHIN ORTHOPAEDIC SURGERY FOR ADULT PATIENTS Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if

More information

Who should read this document 2. Key practice points 2. Background/ Scope/ Definitions 2. What is new in this version 3. Policy/Procedure/Guideline 3

Who should read this document 2. Key practice points 2. Background/ Scope/ Definitions 2. What is new in this version 3. Policy/Procedure/Guideline 3 Antibiotic Prophylaxis in Cranial Neurosurgery Antibiotic Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): as above Authors Division: DCSS & Tertiary

More information

Clostridium Difficile Primer: Disease, Risk, & Mitigation

Clostridium Difficile Primer: Disease, Risk, & Mitigation Clostridium Difficile Primer: Disease, Risk, & Mitigation KALVIN YU, M.D. CHIEF INTEGRATION OFFICER, SCPMG/SCAL KAISER PERMANENTE ASSOCIATE PROFESSOR INFECTIOUS DISEASE, COLLEGE OF GLOBAL PUBLIC HEALTH,

More information

Effeet on Bacterial Growth

Effeet on Bacterial Growth ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 17, p. 36-366 Copyright ( 17 American Society for Microbiology Vol., No. 5 Printed in U.S.A. Automatic Radiometric Measurement of Antibiotic Effeet on Bacterial

More information

Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals

Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.

More information

on February 12, 2018 by guest

on February 12, 2018 by guest AAC Accepted Manuscript Posted Online 12 February 2018 Antimicrob. Agents Chemother. doi:10.1128/aac.00047-18 Copyright 2018 Stapert et al. This is an open-access article distributed under the terms of

More information

Impact of Spores on the Comparative Efficacies of Five Antibiotics. Pharmacodynamic Model

Impact of Spores on the Comparative Efficacies of Five Antibiotics. Pharmacodynamic Model AAC Accepts, published online ahead of print on 12 December 2011 Antimicrob. Agents Chemother. doi:10.1128/aac.01109-10 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions.

More information

against Clinical Isolates of Gram-Positive Bacteria

against Clinical Isolates of Gram-Positive Bacteria ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,

More information

ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections

ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.

More information

EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update

EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/211249/2005-FINAL July 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE DIHYDROSTREPTOMYCIN (Extrapolation to all ruminants)

More information

MICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ

MICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 1062 1066 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Daptomycin,

More information

Antimicrobial Prophylaxis in the Surgical Patient. M. J. Osgood

Antimicrobial Prophylaxis in the Surgical Patient. M. J. Osgood Antimicrobial Prophylaxis in the Surgical Patient M. J. Osgood Outline Definitions surgical site infection (SSI) Risk factors Wound classification Microbiology of SSIs Strategies for prevention of SSIs

More information

Isolation of antibiotic producing Actinomycetes from soil of Kathmandu valley and assessment of their antimicrobial activities

Isolation of antibiotic producing Actinomycetes from soil of Kathmandu valley and assessment of their antimicrobial activities International Journal of Microbiology and Allied Sciences (IJOMAS) ISSN: 2382-5537 May 2016, 2(4):22-26 IJOMAS, 2016 Research Article Page: 22-26 Isolation of antibiotic producing Actinomycetes from soil

More information

European Public MRL assessment report (EPMAR)

European Public MRL assessment report (EPMAR) 18 March 2016 EMA/CVMP/619817/2015 Committee for Medicinal Products for Veterinary Use European Public MRL assessment report (EPMAR) Gentamicin (all mammalian food producing species and fin fish) On 3

More information

Factors affecting plate assay of gentamicin

Factors affecting plate assay of gentamicin Journal of Antimicrobial Chemotherapy (1977) 3, 17-23 Factors affecting plate assay of gentamicin II. Media D. C. Shanson* and C. J. Hince Department of Medical Microbiology, The London Hospital Medical

More information

Q1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants.

Q1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants. Q1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants. C. difficile rarely causes problems, either in healthy adults or in infants.

More information

USA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only

USA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only USA Product Label http://www.vetdepot.com PHARMACIA & UPJOHN COMPANY Division of Pfizer Inc. Distributed by PFIZER INC. 235 E. 42ND ST., NEW YORK, NY, 10017 Telephone: 269-833-4000 Fax: 616-833-4077 Customer

More information

THE HUMAN MICROBIOME: THE INFECTION PREVENTIONIST S BEST FRIEND

THE HUMAN MICROBIOME: THE INFECTION PREVENTIONIST S BEST FRIEND THE HUMAN MICROBIOME: THE INFECTION PREVENTIONIST S BEST FRIEND Michigan Communicable Disease Conference May 4, 2017 Richard A. Van Enk, Ph.D., CIC Director, Infection Prevention and Epidemiology vanenkr@bronsonhg.org

More information

Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran

Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran Letter to the Editor Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran Mohammad Rahbar, PhD; Massoud Hajia, PhD

More information

In Vitro Activity of Netilmicin, Gentamicin, and Amikacin

In Vitro Activity of Netilmicin, Gentamicin, and Amikacin ANTIMICROBIAL AGzNTS AND CHEMOTHERAPY, Jan. 1977, p. 126-131 Copyright X 1977 American Society for Microbiology Vol. 11, No. 1 Printed in U.S.A. In Vitro Activity of Netilmicin, Gentamicin, and Amikacin

More information

.'URRENT THERAPEUTIC RESEA. VOLUME 66, NUMBER 3, MAY/JuNE 2005

.'URRENT THERAPEUTIC RESEA. VOLUME 66, NUMBER 3, MAY/JuNE 2005 .'URRENT THERAPEUTIC RESEA VOLUME 66, NUMBER 3, MAY/JuNE 2005 Efficacy of Moxifloxacin Monotherapy Versus Gatifloxacin Monotherapy, Piperacillin- Tazobactam Combination Therapy, and Clindamycin Plus Gentamicin

More information

ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat

ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic

More information

Randall Singer, DVM, MPVM, PhD

Randall Singer, DVM, MPVM, PhD ANTIBIOTIC RESISTANCE Randall Singer, DVM, MPVM, PhD Associate Professor of Epidemiology Department of Veterinary and Biomedical Sciences University of Minnesota Overview How does resistance develop? What

More information

Improved Susceptibility Disk Assay Method Employing an

Improved Susceptibility Disk Assay Method Employing an ANTIMICROIAL AGENTS AND CHEMOTHERAPY, Nov. 1978, P. 761-764 66-484/78/14-761$2./ pyright 1978 American Society for Microbiology Vol. 14, No. 5 Printed in U.S.A. Improved Susceptibility Disk Assay Method

More information

Antibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents

Antibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents Antibiotic Prophylaxis in Spinal Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Authors Division: DCSS & Tertiary Medicine Unique

More information

Part II SUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 25 mg Clindamycin (as Clindamycin Hydrochloride)

Part II SUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 25 mg Clindamycin (as Clindamycin Hydrochloride) Clindacyl 25mg Tablets Vm 08007/4104 Part II SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CLINDACYL 25 MG TABLETS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet

More information

VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill

VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559 ANTIBIOTIC 6640.* Ill BIOLOGICAL STUDIES WITH ANTIBIOTIC 6640, A NEW BROAD-SPECTRUM AMINOGLYCOSIDE ANTIBIOTIC J. Allan Waitz, Eugene L. Moss, Jr., Edwin

More information

Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1

Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1 Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali Lec 1 28 Oct 2018 References Lippincott s IIIustrated Reviews / Pharmacology 6 th Edition Katzung and Trevor s Pharmacology / Examination

More information

Postantibiotic effect of aminoglycosides on Gram-negative bacteria evaluated by a new method

Postantibiotic effect of aminoglycosides on Gram-negative bacteria evaluated by a new method Journal of Antimicrobial Chemotherapy (1988) 22, 23-33 Postantibiotic effect of aminoglycosides on Gram-negative bacteria evaluated by a new method Barforo Isaksson'*, Lennart Nibson*, Rolf Mailer' and

More information

CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Antibiotics One of the most commonly used group of drugs In USA 23

More information

Anaerobic and microaerophilic gram-positive cocci Peptococcus species, Peptostreptococcus species, Microaerophilic streptococci

Anaerobic and microaerophilic gram-positive cocci Peptococcus species, Peptostreptococcus species, Microaerophilic streptococci CLINDACIN Composition Each capsule contains Clindamycin (as hydrochloride) 150 mg Capsule Action Clindamycin bind exclusively to the 50S subunit of bacterial ribosomes and suppress protein synthesis. Clindamycin

More information

Preventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal

Preventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal Preventing Multi-Drug Resistant Organism (MDRO) Infections For National Patient Safety Goal 07.03.01 2009 Methicillin Resistant Staphlococcus aureus (MRSA) About 3-8% of the population at large is a carrier

More information

SURVIVABILITY OF HIGH RISK, MULTIRESISTANT BACTERIA ON COTTON TREATED WITH COMMERCIALLY AVAILABLE ANTIMICROBIAL AGENTS

SURVIVABILITY OF HIGH RISK, MULTIRESISTANT BACTERIA ON COTTON TREATED WITH COMMERCIALLY AVAILABLE ANTIMICROBIAL AGENTS SURVIVABILITY OF HIGH RISK, MULTIRESISTANT BACTERIA ON COTTON TREATED WITH COMMERCIALLY AVAILABLE ANTIMICROBIAL AGENTS Adrienn Hanczvikkel 1, András Vígh 2, Ákos Tóth 3,4 1 Óbuda University, Budapest,

More information

Overview of C. difficile infections. Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases

Overview of C. difficile infections. Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases Overview of C. difficile infections Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases Conflicts of Interest I have no financial conflicts of interest related to this topic and presentation.

More information

The Effect of Perioperative Use of Prophylactic Antibiotics on Surgical Wound Infection

The Effect of Perioperative Use of Prophylactic Antibiotics on Surgical Wound Infection THE IRAQI POSTGRADUATE MEDICAL JOURNAL PROPHYLACTIC ANTIBIOTICS ON SURGICAL WOUND INFECTION The Effect of Perioperative Use of Prophylactic Antibiotics on Surgical Wound Infection Ahmed Hamid Jasim*, Nabeel

More information

Preventing Clostridium difficile Infection (CDI)

Preventing Clostridium difficile Infection (CDI) 1 Preventing Clostridium difficile Infection (CDI) All Hands on Deck to Reduce CDI Skill Nursing Facility Conference July 28, 2017 Idamae Kennedy, MPH,BSN,RN,CIC Liaison Infection Preventionist Healthcare

More information

Inactivation of Burkholderia mallei in equine serum for laboratory use.

Inactivation of Burkholderia mallei in equine serum for laboratory use. JCM Accepted Manuscript Posted Online 11 February 2015 J. Clin. Microbiol. doi:10.1128/jcm.03141-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10 11 12 13

More information

Clostridium difficile infection: The Present and the Future

Clostridium difficile infection: The Present and the Future Clostridium difficile infection: The Present and the Future Carlos E. Figueroa Castro, MD Assistant Professor, Division of Infectious Diseases Medical College of Wisconsin November 2014 I have made this

More information

Surgical prophylaxis for Gram +ve & Gram ve infection

Surgical prophylaxis for Gram +ve & Gram ve infection Surgical prophylaxis for Gram +ve & Gram ve infection Professor Mark Wilcox Clinical l Director of Microbiology & Pathology Leeds Teaching Hospitals & University of Leeds, UK Heath Protection Agency Surveillance

More information

Alfonso Torress-Cook, Dr.P.H. Director of Epidemiology/Patient Safety Pacific Hospital of Long Beach

Alfonso Torress-Cook, Dr.P.H. Director of Epidemiology/Patient Safety Pacific Hospital of Long Beach Alfonso Torress-Cook, Dr.P.H. Director of Epidemiology/Patient Safety Pacific Hospital of Long Beach Historical overview The myriad causes of hospital acquired diarrhea Microbiology and ecology of Clostridium

More information

APPROVED PACKAGE INSERT. Each capsule contains clindamycin hydrochloride equivalent to 150 mg clindamycin base.

APPROVED PACKAGE INSERT. Each capsule contains clindamycin hydrochloride equivalent to 150 mg clindamycin base. APPROVED PACKAGE INSERT SCHEDULING STATUS: S4 PROPRIETARY NAMEAND DOSAGE FORM: DALACIN C TM 150 mg (Capsules) COMPOSITION: Each capsule contains clindamycin hydrochloride equivalent to 150 mg clindamycin

More information

PILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 1996

PILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 1996 PILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 996 November 996 by Maggie Brett Antibiotic Reference Laboratory ESR Communicable Disease Centre Porirua CONTENTS Page SUMMARY

More information

Community-Associated C. difficile Infection: Think Outside the Hospital. Maria Bye, MPH Epidemiologist May 1, 2018

Community-Associated C. difficile Infection: Think Outside the Hospital. Maria Bye, MPH Epidemiologist May 1, 2018 Community-Associated C. difficile Infection: Think Outside the Hospital Maria Bye, MPH Epidemiologist Maria.Bye@state.mn.us 651-201-4085 May 1, 2018 Clostridium difficile Clostridium difficile Clostridium

More information

Section 10: Antimicrobial Stewardship and Clostridium difficile Infection: A Primer for the Infection Preventionist

Section 10: Antimicrobial Stewardship and Clostridium difficile Infection: A Primer for the Infection Preventionist Section 10: Antimicrobial Stewardship and Clostridium difficile Infection: A Primer for the Infection Preventionist Antimicrobial stewardship may be a relatively new addition to the job responsibilities

More information

Antibiotic Prophylaxis Update

Antibiotic Prophylaxis Update Antibiotic Prophylaxis Update Choosing Surgical Antimicrobial Prophylaxis Peri-Procedural Administration Surgical Prophylaxis and AMS at Epworth HealthCare Mr Glenn Valoppi Dr Trisha Peel Dr Joseph Doyle

More information

EXCEDE Sterile Suspension

EXCEDE Sterile Suspension VIAL LABEL MAIN PANEL PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN READ SAFETY DIRECTIONS FOR ANIMAL TREATMENT ONLY EXCEDE Sterile Suspension 200 mg/ml CEFTIOFUR as Ceftiofur Crystalline Free

More information

Synergism Between Penicillin, Clindamycin, or Metronidazole and Gentamicin Against Species of the Bacteroides melaninogenicus and

Synergism Between Penicillin, Clindamycin, or Metronidazole and Gentamicin Against Species of the Bacteroides melaninogenicus and ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1984, p. 71-77 0066-4804/84/010071-07$02.00/0 Copyright C 1984, American Society for Microbiology Vol. 25, No. 1 Synergism Between Penicillin, Clindamycin, or

More information

International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.

International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access. I J A P B International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access. ISSN: 2454-8375 COMPARISON OF ANTIMICROBIAL ACTIVITY AND MIC OF BRANDED

More information

Antibiotic therapy of acute gastroenteritis

Antibiotic therapy of acute gastroenteritis Antibiotic therapy of acute gastroenteritis Potential goals Clinical improvement (vs control) Fecal eradication of the pathogen and decrease infectivity Prevent complications Acute gastroenteritis viruses

More information

Inhibition of Shigella sonnei and Enterotoxigenic

Inhibition of Shigella sonnei and Enterotoxigenic MICROBIAL ECOLOGY ZN HEALTH AND DISEASE VOL. 2 153-161 (1989) Inhibition of Shigella sonnei and Enterotoxigenic Escherichia coli by Volatile Fatty Acids in Mice P. PONGPECH* and D. J. HENTGES Department

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur... SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT WONDERCEF powder and solvent for solution for injection for horses not intended for the production of foods for human consumption.

More information

Microbiology : antimicrobial drugs. Sheet 11. Ali abualhija

Microbiology : antimicrobial drugs. Sheet 11. Ali abualhija Microbiology : antimicrobial drugs Sheet 11 Ali abualhija return to our topic antimicrobial drugs, we have finished major group of antimicrobial drugs which associated with inhibition of protein synthesis

More information

New Method for Antibiotic Susceptibility Testing

New Method for Antibiotic Susceptibility Testing ANTIMIROBIAL AGENTS AND HEMOTHERAPY, Aug. 1972, p. 51-56 opyright 1972 American Society for Microbiology Vol. 2, No. 2 Printed in U.S.A. New Method for Antibiotic Susceptibility Testing G. N. ROLINSON

More information

Pharmacological Evaluation of Amikacin in Neonates

Pharmacological Evaluation of Amikacin in Neonates ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1975, p. 86-90 Copyright 0 1975 American Society for Microbiology Vol. 8, No. 1 Printed in U.SA. Pharmacological Evaluation of Amikacin in Neonates JORGE B.

More information

Author - Dr. Josie Traub-Dargatz

Author - Dr. Josie Traub-Dargatz Author - Dr. Josie Traub-Dargatz Dr. Josie Traub-Dargatz is a professor of equine medicine at Colorado State University (CSU) College of Veterinary Medicine and Biomedical Sciences. She began her veterinary

More information

Multiple drug resistance pattern in Urinary Tract Infection patients in Aligarh

Multiple drug resistance pattern in Urinary Tract Infection patients in Aligarh Multiple drug resistance pattern in Urinary Tract Infection patients in Aligarh Author(s): Asad U Khan and Mohd S Zaman Vol. 17, No. 3 (2006-09 - 2006-12) Biomedical Research 2006; 17 (3): 179-181 Asad

More information

Gynaecological Surgery in Adults Surgical Antibiotic Prophylaxis

Gynaecological Surgery in Adults Surgical Antibiotic Prophylaxis Gynaecological Surgery in Adults Surgical Antibiotic Prophylaxis Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date

More information

Evaluation of MicroScan MIC Panels for Detection of

Evaluation of MicroScan MIC Panels for Detection of JOURNAL OF CLINICAL MICROBIOLOGY, May 1988, p. 816-820 Vol. 26, No. 5 0095-1137/88/050816-05$02.00/0 Copyright 1988, American Society for Microbiology Evaluation of MicroScan MIC Panels for Detection of

More information

Effect of dalbavancin on the normal intestinal microflora

Effect of dalbavancin on the normal intestinal microflora Journal of Antimicrobial Chemotherapy (00), 1 doi:10.109/jac/dkl1 Advance Access publication 1 July 00 Effect of dalbavancin on the normal intestinal microflora Carl Erik Nord*, Gundars Rasmanis and Elisabeth

More information

Methicillin-Resistant Staphylococcus aureus

Methicillin-Resistant Staphylococcus aureus Methicillin-Resistant Staphylococcus aureus By Karla Givens Means of Transmission and Usual Reservoirs Staphylococcus aureus is part of normal flora and can be found on the skin and in the noses of one

More information

Management of Native Valve

Management of Native Valve Management of Native Valve Infective Endocarditis 2005 AHA 2015 Baddour LM, et al. Circulation. 2015;132(15):1435-86 2009 ESC 2015 Habib G, et al. Eur Heart J. 2015;36(44):3075-128 ESC 2015: Endocarditis

More information

Lactose-Fermenting Bacteria Isolated from Burni Patients

Lactose-Fermenting Bacteria Isolated from Burni Patients INFECTION AND IMMUNITY, March 1971, p. 411-415 Copyright 1971 American Society for Microbiology Vol. 3, No. 3 Printed in U.S.A. Effect of Antibiotic Treatment on the Incidence of Infectious Drug Resistance

More information

MINIREVIEW. Colonization Resistance

MINIREVIEW. Colonization Resistance ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1994, p. 409-414 0066-4804/94/$04.00+0 Copyright 1994, American Society for Microbiology Vol. 38, No. 3 MINIREVIEW Colonization Resistance E. J. VOLLAARD'* AND

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amfipen LA 100 mg/ml suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each ml contains:

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NOSEDORM 5 mg/ml Solution for injection for dogs and cats [DE, ES, FR, PT] 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each

More information

Protozoan, Bacterial, and Volatile Fatty Acid

Protozoan, Bacterial, and Volatile Fatty Acid APPLIED MICROBIOLOGY, Nov. 1967, p. 1417-1421 Copyright 1967 American Society for Microbiology Protozoan, Bacterial, and Volatile Fatty Acid Changes Associated with Feeding Tylosin N. SATAPATHY1 AND D.

More information

Principles of Antimicrobial Therapy

Principles of Antimicrobial Therapy Principles of Antimicrobial Therapy Doo Ryeon Chung, MD, PhD Professor of Medicine, Division of Infectious Diseases Director, Infection Control Office SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE CASE 1

More information

Give the Right Antibiotics in Trauma Mitchell J Daley, PharmD, BCPS

Give the Right Antibiotics in Trauma Mitchell J Daley, PharmD, BCPS Give the Right Antibiotics in Trauma Mitchell J Daley, PharmD, BCPS Clinical Pharmacy Specialist, Critical Care Dell Seton Medical Center at the University of Texas and Seton Healthcare Family Clinical

More information

Learning Objectives 6/1/18

Learning Objectives 6/1/18 Gulf Coast Multidisciplinary Pharmacotherapy Conference Kelly R. Reveles, PharmD, PhD, BCPS College of Pharmacy, The University of Texas at Austin School of Medicine, UT Health San Antonio Email: kdaniels46@utexas.edu

More information

TOLYPOMYCIN, A NEW ANTIBIOTIC. V IN VITRO AND IN VIVO ANTIMICROBIAL ACTIVITY. Masahiro Kondo, Tokiko Oishi and Kanji Tsuchiya

TOLYPOMYCIN, A NEW ANTIBIOTIC. V IN VITRO AND IN VIVO ANTIMICROBIAL ACTIVITY. Masahiro Kondo, Tokiko Oishi and Kanji Tsuchiya 16 THE JOURNAL OF ANTIBIOTICS JAN. 1972 TOLYPOMYCIN, A NEW ANTIBIOTIC. V IN VITRO AND IN VIVO ANTIMICROBIAL ACTIVITY Masahiro Kondo, Tokiko Oishi and Kanji Tsuchiya Biological Research Laboratories, Research

More information

R-factor mediated trimethoprim resistance: result of two three-month clinical surveys

R-factor mediated trimethoprim resistance: result of two three-month clinical surveys Journal of Clinical Pathology, 1978, 31, 850-854 R-factor mediated trimethoprim resistance: result of two three-month clinical surveys S. G. B. AMYES1, A. M. EMMERSON2, AND J. T. SMITH3 From the 'Department

More information

Systemic Antimicrobial Prophylaxis Issues

Systemic Antimicrobial Prophylaxis Issues Systemic Antimicrobial Prophylaxis Issues Pierre Moine Department of Anesthesiology University of Colorado Denver 3 rd International Conference on Surgery and Anesthesia OMICs Group Conference The Surgical

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062

More information

SESSION XVI NEW ANTIBIOTICS

SESSION XVI NEW ANTIBIOTICS SESSION XVI NEW ANTIBIOTICS New Antibiotics to Treat Anaerobic Infections 2 Goldstein, E.J.C.;* Citron, D.M. Antibiotic Pharmacodynamics 3 Stein, G.E.* Targeting Selenium Metabolism in Stickland Fermentors:

More information

Glycopeptide Resistant Enterococci (GRE) Policy IC/292/10

Glycopeptide Resistant Enterococci (GRE) Policy IC/292/10 BASINGSTOKE AND NORTH HAMPSHIRE NHS FOUNDATION TRUST Glycopeptide Resistant Enterococci (GRE) Policy IC/292/10 Supersedes: IC/292/07 Owner Name Dr Nicki Hutchinson Job Title Consultant Microbiologist,

More information